Guy M. Goodwin, MD, affiliated with Compass Pathfinder Ltd in London, United Kingdom, has published extensively on major depressive disorder, bipolar disorder, anxiety, and the therapeutic potential of psychedelics. His work includes studies on psilocybin for treatment-resistant depression, relapse prevention in depression, treatment adherence and cognitive impairment in bipolar disorder, and comparative trials of mood stabilizers and antipsychotics. His research spans from 2004 to 2025 and often involves collaboration with co-authors such as Eduard Vieta and Ana Gonzalez-Pinto.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
